Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleThe State of the Art

The History of Prostate-Specific Membrane Antigen as a Theranostic Target in Prostate Cancer: The Cornerstone Role of the Prostate Cancer Foundation

Andrea K. Miyahira and Howard R. Soule
Journal of Nuclear Medicine March 2022, 63 (3) 331-338; DOI: https://doi.org/10.2967/jnumed.121.262997
Andrea K. Miyahira
Science Department, Prostate Cancer Foundation, Santa Monica, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Howard R. Soule
Science Department, Prostate Cancer Foundation, Santa Monica, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 63 no. 3 331-338
DOI 
https://doi.org/10.2967/jnumed.121.262997
PubMed 
34675109

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Received for publication August 3, 2021
  • Revision received October 8, 2021
  • Published online March 1, 2022.

Article Versions

  • previous version (October 21, 2021 - 13:21).
  • You are viewing the most recent version of this article.
Copyright & Usage 
© 2022 by the Society of Nuclear Medicine and Molecular Imaging.

Author Information

  1. Andrea K. Miyahira and
  2. Howard R. Soule
  1. Science Department, Prostate Cancer Foundation, Santa Monica, California
  1. For correspondence or reprints, contact Andrea K. Miyahira (amiyahira{at}pcf.org).
View Full Text

Statistics from Altmetric.com

Cited By...

  • 23 Citations
  • 27 Citations
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • Dual targeting with 224Ra/212Pb-conjugates for targeted alpha therapy of disseminated cancers: A conceptual approach
    Asta Juzeniene, Vilde Yuli Stenberg, Øyvind Sverre Bruland, Mona-Elisabeth Revheim, Roy Hartvig Larsen
    Frontiers in Medicine 2023 9
  • Expanding Role for Gallium-68 PET Imaging in Oncology
    Janke Kleynhans, Thomas Ebenhan, Mike Machaba Sathekge
    Seminars in Nuclear Medicine 2024 54 6
  • A 2022 International Survey on the Status of Prostate Cancer Theranostics
    Thomas Beyer, Johannes Czernin, Lutz Freudenberg, Frederik Giesel, Marcus Hacker, Rodney J. Hicks, Bernd J. Krause
    Journal of Nuclear Medicine 2023 64 1
  • The 28th Annual Prostate Cancer Foundation Scientific Retreat report
    Andrea K. Miyahira, Howard R. Soule
    The Prostate 2022 82 14
  • Anticancer potential of active alkaloids and synthetic analogs derived from marine invertebrates
    Chunyan Cai, Dejun Yang, Yi Cao, Zhaolei Peng, Yulin Wang, Jingjing Xi, Chunmei Yan, Xiaofang Li
    European Journal of Medicinal Chemistry 2024 279
  • Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
    Joseph P. Gallant, Hallie M. Hintz, Gihan S. Gunaratne, Matthew T. Breneman, Emma E. Recchia, Jayden L. West, Kendahl L. Ott, Erika Heninger, Abigail E. Jackson, Natalie Y. Luo, Zachary T. Rosenkrans, Reinier Hernandez, Shuang G. Zhao, Joshua M. Lang, Labros Meimetis, David Kosoff, Aaron M. LeBeau
    Cancer Research Communications 2024 4 6
  • Positron emission tomography: Evolving modalities, radiopharmaceuticals and professional collaboration
    Sally L. Ayesa, Andrew Murphy
    Journal of Medical Radiation Sciences 2022 69 4
  • Emerging Theranostics for Prostate Cancer and a Model of Prostate-specific Membrane Antigen Therapy
    Kerry Jewell, Michael S. Hofman, Jeremy S. L. Ong, Sidney Levy
    Radiology 2024 311 1
  • Exploiting the DNA Damage Response for Prostate Cancer Therapy
    Travis H. Stracker, Oloruntoba I. Osagie, Freddy E. Escorcia, Deborah E. Citrin
    Cancers 2023 16 1
  • Agreement between PSMA-RADS and E-PSMA systems in classifying [18F]PSMA-1007 PET/CT lesions among prostate cancer patients: exploring the correlation between lesion size and uptake
    Miguel Mendoza-Ávila, Hiram Esparza-Pérez, Juan Andrés Castillo-López, Edel Rafael Rodea-Montero
    Frontiers in Medicine 2024 11

Article usage

Article usage: October 2021 to April 2025

AbstractFullPdf
Oct 20211450070
Nov 2021778040
Dec 2021346010
Jan 202221909
Feb 2022188013
Mar 20222453336906
Apr 2022233364187
May 2022167311112
Jun 202211434490
Jul 2022183389140
Aug 20228023398
Sep 20229929785
Oct 20225626692
Nov 20226616896
Dec 20225743670
Jan 20236242997
Feb 202345438105
Mar 202350489103
Apr 20233537690
May 20234022670
Jun 20232624364
Jul 20232532264
Aug 202326418123
Sep 20232636567
Oct 20232821696
Nov 20233924291
Dec 20231516856
Jan 20242822367
Feb 20242235278
Mar 202424211128
Apr 20245516480
May 20243818199
Jun 20244216966
Jul 202410725172
Aug 20248625985
Sep 20241416977
Oct 20242024474
Nov 202434264114
Dec 202425371117
Jan 202526250116
Feb 20252235294
Mar 202516373135
Apr 202522432162
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 63 (3)
Journal of Nuclear Medicine
Vol. 63, Issue 3
March 1, 2022
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The History of Prostate-Specific Membrane Antigen as a Theranostic Target in Prostate Cancer: The Cornerstone Role of the Prostate Cancer Foundation
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
The History of Prostate-Specific Membrane Antigen as a Theranostic Target in Prostate Cancer: The Cornerstone Role of the Prostate Cancer Foundation
Andrea K. Miyahira, Howard R. Soule
Journal of Nuclear Medicine Mar 2022, 63 (3) 331-338; DOI: 10.2967/jnumed.121.262997

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
The History of Prostate-Specific Membrane Antigen as a Theranostic Target in Prostate Cancer: The Cornerstone Role of the Prostate Cancer Foundation
Andrea K. Miyahira, Howard R. Soule
Journal of Nuclear Medicine Mar 2022, 63 (3) 331-338; DOI: 10.2967/jnumed.121.262997
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • BIRTH: DISCOVERY AND EARLY CHARACTERIZATION
    • YOUTH: EARLY EVIDENCE OF UTILITY
    • ADOLESCENCE: TRANSLATION
    • ADULT: THERANOSTICS REVOLUTION
    • THE CORNERSTONE ROLE OF PCF IN PSMA THERANOSTICS
    • CONCLUSION
    • DISCLOSURE
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • A 2022 International Survey on the Status of Prostate Cancer Theranostics
  • Google Scholar

More in this TOC Section

  • Rethinking Dosimetry: A European Perspective
  • A Vision for Gastrin-Releasing Peptide Receptor Targeting for Imaging and Therapy: Perspective from Academia and Industry
  • Treatment Landscape of Prostate Cancer in the Era of PSMA Radiopharmaceutical Therapy
Show more The State of the Art

Similar Articles

Keywords

  • theranostics
  • prostate cancer
  • PSMA
  • PET imaging
  • molecular radiotherapy
SNMMI

© 2025 SNMMI

Powered by HighWire